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While hematopoietic stem cell (HSC) self-renewal is
well studied, it remains unknown whether distinct
control mechanisms enable HSC divisions that
generate progeny cells with specific lineage bias.
Here, we report that the monocytic transcription
factor MafB specifically restricts the ability of M-
CSF to instruct myeloid commitment divisions in
HSCs. MafB deficiency specifically enhanced sensi-
tivity to M-CSF and caused activation of the myeloid
master-regulator PU.1 in HSCs in vivo. Single-cell
analysis revealed that reduced MafB levels enabled
M-CSF to instruct divisions producing asymmetric
daughterpairswithonePU.1+cell. Asaconsequence,
MafB/ HSCs showed a PU.1 and M-CSF receptor-
dependent competitive repopulation advantage
specifically in the myelomonocytic, but not T
lymphoid or erythroid, compartment. Lineage-biased
repopulationadvantagewasprogressive,maintained
long term, and serially transplantable. Together, this
indicates that an integrated transcription factor/cyto-
kine circuit can control the rate of specific HSC
commitment divisions without compromising other
lineages or self-renewal.
INTRODUCTION
The different short-lived cell types of mammalian blood are
continuously regenerated from a small population of hematopoi-300 Cell 138, 300–313, July 24, 2009 ª2009 Elsevier Inc.etic stem cells (HSCs) in the bone marrow (Bryder et al., 2006).
Although a significant proportion of HSCs with long-term recon-
stitution potential is predominantly quiescent or divides infre-
quently (Wilson et al., 2008), HSCs need to enter the cycle to
continuously regenerate mature blood cells in a correctly
balanced ratio or to replenish the stem cell pool under stress
conditions. Cell division of HSCs may thus result in self-renewal
divisions or the production of more differentiated progeny (Or-
ford and Scadden, 2008). Although such downstream progeni-
tors still retain a high degree of multipotency, recent advances
in their characterization also suggest that early diversification
into cells with distinct lineage bias can occur at the most primi-
tive stem and precursor cell level (Dykstra et al., 2007; Iwasaki
and Akashi, 2007; Luc et al., 2008). However, the mechanisms
controlling such specific lineage engagement divisions remain
elusive.
Several cellular regulators have been identified that can either
promote or restrict HSC cycling, but their mutation in genetic
models exclusively affected self-renewal (Orford and Scadden,
2008; Zon, 2008). By contrast, regulators that selectively control
lineage-specific commitment divisions of HSCs have not been
identified. In this context, the importance of both transcription
factor and cytokine signaling for lineage engagement has been
invoked (Metcalf, 2007, 2008; Orkin and Zon, 2008; Sieweke
and Graf, 1998; Zhang and Lodish, 2008), but no clear mecha-
nism has emerged as to how these two critical control elements
might be integrated. Transcription factors with effects on stem
cell cycling so far were exclusively found to affect self-renewal
divisions (Orford and Scadden, 2008; Zon, 2008). As for cytokine
receptors, several of them are expressed on primitive hemato-
poietic stem and precursor cells (Akashi et al., 2003; Hu et al.,
1997; Miyamoto et al., 2002), but it has been a long-standing
debate whether cytokine signaling has instructive or permissive
effects on lineage commitment (Enver et al., 1998; Metcalf,
1998). On the one hand, observations that differentiation can
occur in the absence of lineage-specific cytokine signaling and
that ectopic receptor expression can induce proliferation without
commitment to the cytokine affiliated pathway (Enver et al.,
1998; Lagasse and Weissman, 1997; McArthur et al., 1994; Met-
calf, 2008) have been interpreted as a permissive role of cytokine
signaling in lineage engagement. On the other hand, examples
have been reported where ectopic cytokine signals resulted in
lineage conversion and thus supported an instructive model
(Kondo et al., 2000; Pawlak et al., 2000).
MafB is a bZip type transcription factor that is highly ex-
pressed in mature monocytes and macrophages (Eichmann
et al., 1997; Kelly et al., 2000; Sieweke et al., 1996). Overexpres-
sion of MafB limits myeloid progenitor proliferation (Tillmanns
et al., 2007) and accelerates macrophage differentiation (Gemelli
et al., 2006; Kelly et al., 2000) at the expense of other cell fate
options (Bakri et al., 2005; Sieweke et al., 1996). Furthermore,
MafB-deficient macrophages show increased responsiveness
to M-CSF-induced morphological changes (Aziz et al., 2006).
M-CSF has been mainly characterized for its lineage-specific
effects on monocytes and macrophages (Pixley and Stanley,
2004), but earlier work also suggested that M-CSF can act on
primitive stem and precursor cell populations (Kriegler et al.,
1994), which upon more detailed characterization were also
found to express its receptor (Akashi et al., 2003; Miyamoto
et al., 2002).
Here, we report that MafB deficiency specifically sensitized
HSC populations to M-CSF-induced cell division, specific upre-
gulation of the early myeloid selector gene PU.1, and a dramati-
cally enhanced myeloid-specific repopulation activity that does
not affect self-renewal or differentiation into other lineages. Our
results point to a role for MafB in the maintenance of a balanced
lineage potential of HSCs by selectively restricting myeloid
commitment divisions that give rise to PU.1+ progenitors in
response to M-CSF signaling. Together, these data suggest
that the potential of stem cells to produce differentiated progeny
of a specific lineage bias can be subject to control by integrated
cytokine/transcription factor circuits, where variation in cell-
intrinsic sensitivity limits like those set by MafB can render
external cues such as M-CSF instructive.
RESULTS
Myeloid Lineage-Specific Repopulation Advantage
of MafB/ HSCs
Hematopoietic transcription factors with established roles in
mature myeloid cells can have important functions in HSCs (Iwa-
saki and Akashi, 2007; Orford and Scadden, 2008; Orkin and
Zon, 2008; Zon, 2008). Here, we found significant expression
of the monocyte/macrophage transcription factor MafB in the
highly LT-HSC-enriched CD34Flt3/Flk2 population of the
primitive c-kit+,sca+,lin (KSL) bone marrow fraction but not
in downstream progenitors such as in Flt3+KSL multipotent
progenitors (MPPs) or in committed common myeloid (CMPs)
and granulocyte macrophage (GMPs) progenitors (Figures S1A
and S1B available online). Since MafB can influence cellular
proliferation in other systems and cell-cycle status is animportant determinant of stem cell activity, we further investi-
gated the effect of MafB deficiency on HSC proliferation. Cell-
cycle analysis consistently revealed an increased rate of cell divi-
sion for MafB/ cells in highly LT-HSC-enriched populations as
defined by two different stringent marker combinations (CD150+
or CD34 cells in the Flt3 KSL [KSLF] fraction) but not in other
KSL fractions (Figures 1A, 1B, S1C, and S1D). When we further
analyzed the consequence of increased HSC proliferation on
stem cell activity in competitive reconstitution assays, we
observed a significant advantage of MafB/ but not WT HSCs
over normal competitors that resulted in an increased contribu-
tion ofMafB/ cells to the KSL fraction (Figure 1C). Surprisingly,
this competitive advantage of MafB/ HSCs differentially
affected the repopulation of lymphomyeloid progeny and re-
sulted in striking differences in the contribution to the different
lineages of the hematopoietic system. Twelve weeks after recon-
stitution, myeloid Mac1+ cells in spleen and bone marrow were
largely derived from MafB/ donor cells with a 3-fold and 11-
fold excess over WT competitors, respectively (Figure 1D). This
competitive advantage was maintained long term in the KSL
fraction (Figures S2A and SB) and in mature myeloid cells,
including F4/80+ macrophages (Figure 1D). Interestingly, how-
ever, the repopulation advantage was lineage specific and not
observed in lymphoid or erythroid cells. In peripheral lymphoid
organs or bone marrow, the original ratio of donor to competitor
was maintained in T cells and only slightly increased in B cells
(Figure 1D). Since erythroid cells only weakly express the Ly5
surface marker, we analyzed MafB/ donor contribution to
Ter119+ erythroid cells in the bone marrow by quantitative
genomic PCR. Quantitative PCR of nonfunctional GFP se-
quences that specifically tag the MafB knockout allele (Blanchi
et al., 2003) revealed a linear standard curve for defined mixtures
of WT and MafB/ cells (Figures 1E and 1F) and a consistent
advantage of MafB/ donor cell contribution to Mac-1+ cells
but a contribution to the erythroid lineage that reflected the orig-
inal injected donor to competitor ratio (Figure 1G).
Despite this strong myeloid-biased repopulation advantage,
we did not observe an abnormal increase of total KSL (Figures
S2C and S2D) or myeloid cells, myeloproliferative disorders, or
leukemia (Figure S3), indicating that MafB/ HSCs outcom-
peted WT cells in the generation of myeloid progeny without
transgressing compartment limits.
To further define the efficiency and kinetics of the myeloid
specific repopulation advantage, we followed the contribution
of MafB/ HSCs to blood leukocytes of mice reconstituted in
excess of competitor cells. Whereas at all dilutions MafB/
stem cells continued to stably contribute to T cells at the initially
injected ratio over the whole observation period, we observed a
progressively increasing contribution of MafB/ Ly5.2 but not
WT Ly5.2 cells to myeloid Mac-1-positive leukocytes even at a
10-fold or 50-fold excess of competitor cells (Figure 2A). This
became first observable between 4 and 6 weeks after reconsti-
tution, when originally coinjected progenitors have exhausted
their life span and peripheral blood cells will be mainly derived
from donor stem cells. At 15 weeks after reconstitution with
equal initial input, MafB/ cells had almost entirely outcom-
peted the WT cells, and in the case of a 10-fold initial competitor
excess still provided most cells in the Mac-1-positive population.Cell 138, 300–313, July 24, 2009 ª2009 Elsevier Inc. 301
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A B Figure 1. Increased Proliferation and Myeloid Repo-
pulation Bias of MafB/ HSCs
(A) DNA content of highly LT-HSC-enriched bone marrow
CD150+ KSLF cells.
(B) Percent cells in S/G2/M of different KSL populations (from
profiles in A and Figures S1C and S1D).
(C) Contribution of WT or MafB/ (KO) Ly5.2 donor (blue) and
WT Ly5.1 competitor cells (red) to the KSL population 8 weeks
after transplantation with 3-fold excess of competitor (left) and
average donor to competitor ratios (right, n = 4).
(D) Contribution ofMafB/ (KO) Ly5.2 cells to different mature
lymphoid and myeloid populations showing KO:WT compet-
itor cell ratio (Ly5.2:Ly5.1) of pooled samples 12 weeks (n = 4)
or 28 weeks (n = 5) after reconstitution with a mutant to
competitor input ratio of 1/1 or 2/1, respectively.
(E) Flow chart of combined FACS and genomic qPCR analysis
of mutant allele-specific GFP sequences for MafB/ cell
contribution to lymphoid, myeloid, and erythroid cells.
(F) Standard curve of genomic qPCR for defined mixtures of
MafB/ and WT bone marrow.
(G) Contribution of MafB/ (KO) Ly5.2 cells to lymphoid,
myeloid, and erythroid populations in blood and bone marrow
13 weeks after reconstitution at a mutant to competitor ratio of
1/1 by FACS or genomic qPCR analysis (n = 3).
Error bars indicate the standard error of the mean.302 Cell 138, 300–313, July 24, 2009 ª2009 Elsevier Inc.
Strikingly, even at the initial ratio of 1/50, which corresponded to
the arithmetic equivalent of 0.2 to 0.6 MafB/ LT-HSCs
(assuming a LT-HSC frequency of 1–3/100,000 cells; Bryder
et al. [2006]), one out of four injected mice showed a progressive
and principally MafB/ contribution to the myeloid compart-
ment by 15 weeks after reconstitution, whereas the three other
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Figure 2. Kinetics and Serial Transplantation of
Myeloid Repopulation Bias of MafB/ HSCs
(A) Ly5.1 mice were reconstituted at the indicated input ratios
of MafB/ (KO) or WT control Ly5.2 to WT Ly5.1/Ly5.2 (F1)
competitor cells. Host, donor, and competitor contribution to
Mac-1+ myeloid and control CD33+ lymphoid blood cells
were analyzed by FACS (representative profile in Figure S4)
and plotted as donor to competitor cell ratio (n = 4 for 1/1
and 1/10).
(B) Donor to competitor ratios in myeloid and T lymphoid blood
cells 6 weeks after total bone marrow transplantation from
a primary reconstituted mouse with an original 1/10 KO:WT
ratio into secondary (at 23 weeks, n = 10) and tertiary (at
25 weeks, n = 5) recipients.
(C) Survival rates from serial transplantation of WT andMafB/
day 12 CFU-S (n = 5).
Error bars indicate the standard error of the mean.
mice had no Ly5.2 contribution. Together, these
results indicated that even at a vast excess of
competitor cells, few, possibly a single, MafB/
stem cells could rapidly and progressively outcom-
pete normal cells in the repopulation of the myeloid
compartment but continued to contribute faithfully
at original ratios to the development of T cells.
Myeloid-Biased Repopulation through Serial
Transplantation
Increased proliferative potential of HSCs is
frequently associated with stem cell exhaustion
and eventual hematopoietic failure of bone marrow
transplants (Orford and Scadden, 2008). To deter-
mine whether this was the case for MafB/
HSCs, we investigated whether a myeloid selective
repopulation advantage could be sustained
through serial transplantations. As shown in
Figure 2B, serial bone marrow transfer from mice
originally reconstituted with a 10-fold excess of
competitor cells into secondary and tertiary hosts
resulted in continued lymphohematopoietic recon-
stitution for a cumulative period of over one year
and a progressively increasing contribution of
MafB/ HSCs to the myeloid compartment. By
contrast, MafB/ HSCs continued to faithfully
contribute to the T cell lineage at the originally
injected ratio. Furthermore, self-renewal was not
abnormally increased, as serial transplantation
did not affect the total number of KSL cells in the
bone marrow (Figure S5). Repeated transfer of
CFU-S12 colonies from competitive WT or
MafB/ reconstitutions also showed complete
hematopoietic failure and death of recipients after
the fifth transplantation (Figure 2C), as expected from previous
reports (Siminovitch et al., 1964). Taken together, our results
indicate that MafB/ HSCs neither abnormally exhaust nor
increase their self-renewal capacity, continue to contribute to
all lineages, and sustain a progressively increasing myeloid
repopulation advantage through serial transplantation.Cell 138, 300–313, July 24, 2009 ª2009 Elsevier Inc. 303
MafB Deficiency Confers a Specific Advantage
in Generating Myeloid Progeny in Culture
We next investigated whether the myeloid-specific repopulation
advantage of MafB/ HSCs was cell intrinsic and was reflected
in increased generation of myeloid progeny in culture. Toward
this end, we cultured sorted KSL cells under myeloid differentia-
tion conditions in SCF, TPO, and M-CSF (Iwama et al., 2004) or in
the presence of Flt-3 ligand and Il-7 on OP9-DL1 cells, which
support T cell differentiation from HSC populations (Schmitt
and Zuniga-Pflucker, 2002). Cell counts at 24 hr intervals re-
vealed that after 4.5 days under myeloid conditions, MafB/
cells had generated significantly more progeny cells than their
WT counterparts (Figure 3A). By contrast, MafB/ cells showed
no difference from WT cells under lymphoid differentiation condi-
tions (Figure 3B). Notably, the increased cell production under
myeloid conditions did not prevent differentiation or change
the final phenotype of differentiated cells, as judged by a similar
Mac-1/Gr-1 or CD25/CD44 expression profile after 5 days of
myeloid or T cell differentiation conditions, respectively (Figures
3A and 3B). Furthermore, increased generation of myeloid
progeny from MafB/ KSL cells depended on an increased
response to myeloid conditions during the initial culture period
(Figure 3C), whereas myeloid-committed CMPs responded well
but showed no difference between WT and MafB/ samples
(Figure 3D). Consistent with this and in contrast to KSL cell
controls, purified sca, ckit+ progenitors that include CMP also
couldn’t initiate a myeloid specific repopulation advantage
in vivo (Figure S6). Together, these observations indicated that
the increased proliferation and myeloid specific repopulation
advantage of MafB/ HSCs corresponded to an intrinsic
capacity to specifically generate more myeloid progeny in culture.
MafB Specifically Limits Sensitivity to M-CSF Signaling
The ability of MafB/ KSL cells to generate more myeloid
progeny was only observed in the presence but not in the
absence of M-CSF (Figure 3C). Furthermore, other myeloid cyto-
kines such as GM-CSF, Il-3, and G-CSF or FGF, a cytokine with
profound effects on HSCs (Zhang and Lodish, 2008) that acts
through a similar receptor tyrosine kinase as M-CSF, also had
no differential effect (Figure 3E). When we further investigated
this M-CSF response in vivo by cell-cycle analysis 16 hr after
direct injection of recombinant M-CSF into the blood stream of
WT or MafB/ reconstituted mice, we also observed a signifi-
cant increase in the cycling fraction of MafB/ KSL cells but
not of c-kit+sca- progenitors (Figures 3F and 3G).
This enhanced M-CSF-specific response could depend on
increased M-CSF receptor (M-CSFR) expression, increased
cellular sensitivity to M-CSFR signaling, or both. Although we
observed a small increase of M-CSFR message levels both in
total KSL and HSC-enriched KSLF cells (Figures S7A and
S7B), this effect appeared to be too small to account for the
observed phenotype and may simply occur as a secondary
effect of higher sensitivity to receptor signaling, since the expres-
sion of M-CSFR is under positive feedback control from its own
signals (Xie et al., 2001). To uncouple M-CSFR signaling from
regulation of its promoter, we therefore infected WT or MafB/
cyclophosphamide-mobilized stem/precursor cells with a td-
tomato retrovirus expressing a constitutively active form of304 Cell 138, 300–313, July 24, 2009 ª2009 Elsevier Inc.M-CSFR (M-CSFR*), whose signaling and expression is inde-
pendent of exogenous M-CSF (Carlberg and Rohrschneider,
1994). After 36 hr in culture, we observed a significant increase
of cycling cells (S/G2/M) in M-CSFR* over control virus infected
MafB/ KSL cells but not in WT KSL cells or in the uninfected td-
tomato population (Figures 4A and 4B). To further test whether
conversely, ectopic MafB expression could specifically restrict
M-CSFR dependent myeloid divisions under conditions of un-
coupled receptor expression and signaling, we used a condition-
ally transformed T lymphoid cell line that ectopically expresses
M-CSFR from a heterologous, M-CSF-independent promoter
and does not express endogenous MafB or M-CSFR (EGER-
fms; Bourette et al. [2007]). After infection with a MafB-GFP or
GFP control retrovirus, we cultured this cell line alternatively
under myeloid or lymphoid conditions in M-CSF or Il-7/SCF,
respectively. BrdU incorporation and cell-cycle analysis re-
vealed that MafB almost completely inhibited M-CSF-depen-
dent cell division, but had no effect on cell-cycle progression
under lymphoid conditions (Figures 4C and 4D). Thus, both
gain- and loss-of-function experiments in multipotent cells
revealed that MafB can selectively limit sensitivity to M-CSFR
signaling.
To further test whether increased sensitivity to endogenous M-
CSF signaling was at the basis of the myeloid-specific repopula-
tion advantage of MafB/ HSCs in vivo, we generated a GFP
retrovirus expressing short hairpin RNA (shRNA) directed against
the M-CSFR (shFms), which was highly effective in reducing its
surface expression (Figure 4E). We infected MafB/ Ly5.2 fetal
liver cells with shFms virus, injected them together with F1
competitor cells into lethally irradiated Ly5.1 recipients, and
analyzed the effect on competitive repopulation in the spleen,
where a myeloid-specific advantage of MafB/ HSCs could
already be detected 12 days after reconstitution (Figure S8).
Comparison of GFP+ and GFP populations in the Mac-1+ and
Mac-1 fraction of shFms virus-infected donor cells revealed
that reduction of M-CSFR levels decreased the myeloid-specific
repopulation advantage of MafB/ cells (Figure 4F), whereas a
control virus had no such effect (data not shown). Together,
these results indicated that MafB/ HSCs are sensitized to
M-CSF-driven myeloid repopulation in vivo.
MafB Limits M-CSF Instructed Myeloid Commitment
To further test whether higher M-CSF sensitivity specifically re-
sulted in increased myeloid commitment divisions of MafB/
HSCs, we analyzed M-CSF-dependent activation of PU.1, a
myeloid master regulator that is both required for and sufficient
to drive myeloid fate (Iwasaki and Akashi, 2007) and is important
for the initial steps of differentiation, as myeloid precommitted
PU.1+ progenitors (PU.1+ MPPs) can already be detected in
the Flt3+ fraction of KSL cells (Arinobu et al., 2007). Quantitative
RT-PCR revealed that PU.1 was expressed only at very low
levels in MafB/ or WT cells of the HSC-enriched KSLF popula-
tion but increased dramatically in MafB/ cells after 16 hr of
M-CSF stimulation (Figure 5A). Immunofluorescence also
confirmed an increase in PU.1 protein levels and the number of
PU.1+ cells (Figure 5B). By contrast, M-CSF-stimulated MafB/
cells showed no change or reduced expression levels of
erythroid and lymphoid lineage transcription factors (Figure 5C).
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Figure 3. Myeloid-Specific Growth Advantage Is Cell Intrinsic and M-CSF Dependent
(A and B) Cumulative cell counts of FACS-sorted KSL cells (n = 6) under myeloid (A) or T cell differentiation (B) conditions and Mac-1/Gr-1 or CD44/CD25 profile on
day 5.
(C and D) FACS-sorted KSL (C) or CMP (D) cells (n = 6) were cultured in the absence or presence of M-CSF and counted after 16 hr and 40 hr.
(E) Fold increase in cell number of MafB/ over WT cells after 40 hr culture of 60 FACS-sorted KSL cells with M-CSF, GM-CSF, Il-3, G-CSF, or FGF.
(F and G) Cell-cycle analysis showing BrdU/7-AAD profiles (F) and cycling indices (S/G2/M to G0/G1) (G) of bone marrow KSL cells (pink) and sca progenitors
16 hr after IV injection of 5 mg rM-CSF. **p < 0.01 by two-tailed Mann-Whitney test.
Error bars indicate the standard error of the mean.Cell 138, 300–313, July 24, 2009 ª2009 Elsevier Inc. 305
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This indicated that MafB deficiency specifically enabled M-CSF-
dependent activation of the early myeloid commitment factor
PU.1.
To further characterize M-CSF-dependent myeloid commit-
ment divisions, we made use of PU.1-GFP reporter mice that
make it possible to clearly distinguish PU.1 Flt3 HSC and
precursor populations (PU.1 KLSF) from precommitted PU.1+
Flt3+ progenitors (PU.1+ MPPs) within the KSL fraction (Arinobu
et al., 2007). As shown in Figure 6A, MafB was highly expressed
in the PU.1 KLSF fraction but not in PU.1+ MPPs, suggesting
that development of such progenitors from HSCs requires
MafB downregulation. To test whether reduced MafB levels
could thus facilitate M-CSF-induced generation of PU.1+ MPPs
from PU.1 KLSF cells, we crossed the MafB knockout allele
on the PU.1-GFP reporter background and sorted PU.1 KSLF
cells (population A in Figure 6A) from heterozygous MafB+/
PU.1-GFP or WT PU.1-GFP fetal livers (MafB/ PU.1-GFP
embryos not being viable). As shown in Figure 6B, 20 hr stimula-
tion with M-CSF but not with Il-3 resulted in increased PU.1+
cells in MafB+/ samples. Since HSCs and precursor cells do
not divide more than once during this time (Wu et al. [2007];
S.S. and M.H.S., unpublished data) the development of PU.1+
progenitors from PU.1 KLSF cells demonstrated that reduced
MafB dosage specifically enables M-CSF-stimulated myeloid
commitment divisions in PU.1 KSLF cells. To further confirm
this, we sorted PU.1 KSLF cells directly into 384-well plates
and revisited single cells by microscopy until their first division
and monitored the activation of the PU.1-GFP reporter in the
daughter cells. As shown in Figure 6C, we could detect both divi-
sions giving rise to symmetric PU.1/PU.1 and PU.1+/PU.1+
daughter pairs and divisions giving rise to asymmetric PU.1/
PU.1+ daughter pairs. Significantly, reduced MafB dosage selec-
tively increased the development of mixed PU.1/PU.1+
daughter pairs, indicating that MafB deficiency specifically
enhanced M-CSF-driven asymmetric myeloid commitment divi-
sions of KLSF stem and precursor cell populations.
To further confirm that MafB deficiency also enabled
increased myeloid commitment of highly enriched HSC popula-
tions in vivo, we FACS sorted CD150+ KSLF cells, labeled them
with CSFE, and directly injected them into the spleen of irradi-
ated hosts (Figure 7A), a hematopoietic organ that provides
appropriate stem cell niches for extra-medullary hematopoiesis
after HSC mobilization or transplantation (Kiel and Morrison,
2008). In spleens recovered 24 hr after transplantation, we could
clearly detect CFSE+ cells and unambiguously distinguish PU.1-expressing and PU.1-negative cells by anti-PU.1 immunofluo-
rescence (Figure 7B). Sectioning of the whole organ and analysis
of every other section recovered about 1%–2% of injected donor
cells, but whereas only a small proportion of WT cells were found
to express PU.1, a large majority ofMafB/ cells was PU.1 posi-
tive (Figures 7C and 7D). Together, these data demonstrated that
MafB deficiency also enabled increased commitment of highly
purified HSCs to PU.1+ cells in a normal hematopoietic environ-
ment in vivo.
To finally test whether PU.1 activation was required for the
myeloid repopulation advantage of MafB/ HSCs in vivo, we
generated several GFP retroviruses expressing shRNA directed
against PU.1, one of which was highly effective in reducing PU.1
levels (shPU.1/3; Figure 6D). We infected MafB/ Ly5.2 fetal
liver cells with shPU.1/3, injected them together with F1 compet-
itor cells into lethally irradiated Ly5.1 recipients, and analyzed the
effect on competitive repopulation in the spleen as described
above (Figures S8 and 4F). Comparison of GFP+ and GFP pop-
ulations in the Mac-1+ and Mac-1 fraction of shPU.1 virus-in-
fected donor cells revealed that reduction of PU.1 levels
decreased the myeloid-specific repopulation advantage of
MafB/ cells (Figure 6E). These results further indicated that
PU.1 activation is required for the myeloid repopulation advan-
tage of MafB/ HSCs in vivo.
DISCUSSION
Here, we reported that MafB activity restricts M-CSF-induced
myeloid commitment divisions of HSCs. Our data support a
direct instructive effect of M-CSF on HSCs rather than a permis-
sive action on the amplification of down stream progenitors.
The primitive KSL fraction of the bone marrow contains,
besides LT-HSCs in the CD34/Flt-3 compartment, CD34+
and Flt3+ MPPs, which not only have a more limited self-renewal
potential (Bryder et al., 2006) but can also exhibit different
lineage bias (Iwasaki and Akashi, 2007; Luc et al., 2008), in
particular the mutually exclusive GATA-1+ and PU.1+ subpopula-
tions of the CD34+ KSL fraction that are precommitted to distinct
lineages (Arinobu et al., 2007). Several results indicate that MafB
restricts M-CSF-dependent commitment of HSCs to PU.1+
MPPs rather than M-CSF-dependent amplification of such
progenitors after their generation. First, MafB is expressed in
immunophenotypic HSCs (CD34 Flt3 KSL) but not in PU.1+
MPPs. Furthermore, we observed increased proliferation of
MafB/ HSCs using two stringent immunophenotypicFigure 4. MafB Specifically Restricts Sensitivity to M-CSF Signaling
(A) Cyclophosphamide-mobilized stem and precursor cells from MafB/ bone marrow were infected with a td-tomato control virus or a retrovirus expressing
a constitutively active M-CSFR (M-CSFR*) to analyze cell-cycle profiles of td-tomato+ cells in the KSL fraction after 36 hr culture without M-CSF.
(B) Ratio of the cycling index (S/G2/M to G0/G1) for M-CSFR* to control virus infected cells, for the td-tomato+ and td-tomato fraction of WT and MafB/ KSL
samples (n = 2) as shown in (A).
(C) EGER-fms T cells that ectopically express M-CSFR were infected with MafB-GFP retrovirus or GFP control virus to analyze the cell-cycle profiles of GFP+ cells
after 6 hr culture in T cell (SCF, IL-7) or M-CSF conditions.
(D) Ratio of the cycling index (S/G2/M to G0/G1) for MafB to control virus infected cells under T cell and M-CSF conditions as shown in (C) (n = 2).
(E) M-CSFR cell surface expression on HEK293 cells cotransfected with M-CSFR expression vector and anti-M-CSFR shRNA (shFms) or empty control vector.
(F) Analysis of spleen 11 days after transplantation of Ly 5.1 recipients with shFms-GFP retrovirus infectedMafB/ (KO) Ly 5.2 fetal liver cells and WT F1 compet-
itor cells. Representative FACS profiles of KO donor and WT competitor contribution to Mac-1+ myeloid cells in GFP (blue) or shFms-GFP infected GFP+ pop-
ulations (green) and quantification of KO:WT ratios in GFP and GFP+ populations of Mac-1+ and Mac-1 spleen cells (n = 4).
Error bars indicate the standard error of the mean.Cell 138, 300–313, July 24, 2009 ª2009 Elsevier Inc. 307
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Figure 5. MafB Deficiency Enables M-CSF-Dependent PU.1 Activa-
tion
(A) Analysis of relative PU.1 message levels by qRT-PCR in KSLF cells before
and after 16 hr incubation with 100 ng/ml M-CSF, showing primary Ct and
HPRT normalized values.
(B) Analysis of PU.1 protein expression by immunofluorescence on KSLF cells
before and after 6 hr incubation with 100 ng/ml M-CSF. Assembled image of
randomly chosen cells.
(C) Fold changes of lineage-specific transcription factor expression in KSLF
cells after culture with M-CSF, measured by qRT-PCR under the same condi-
tions as in (A).
Error bars indicate the standard error of the mean.308 Cell 138, 300–313, July 24, 2009 ª2009 Elsevier Inc.definitions (CD34 Flt3 KSL or CD150+ Flt3 KSL) but not in any
of the CD150, CD34+, or Flt3+ MPP populations, which would
be expected to show increased cycling in a permissive mecha-
nism that depends on the amplification of progenitors after
commitment. Since in addition MafB/ HSCs showed a
myeloid-specific repopulation advantage without expansion of
the stem cell pool, this is highly consistent with increased
commitment divisions of HSCs. Furthermore, reduced MafB
dosage specifically enabled M-CSF-dependent generation of
PU.1+ daughter cells from individual PU.1 KSLF cells during
the first cell division. Since these cells were PU.1 negative before
exposure to M-CSF and were only analyzed for one cell division,
this experiment excluded selection of pre-existing PU.1+ cells or
the amplification of PU.1+ daughter cells after a stochastic
commitment event. Finally, MafB deficiency increased myeloid
commitment not only in KSLF cells (that also contain ST-HSCs)
in culture but also in individual CD150+ KSLF cells in vivo. Trans-
plantation of these highly LT-HSC-enriched cells into the spleen,
a hematopoietic organ that provides appropriate stem cell
niches (Kiel and Morrison, 2008), showed a dramatically
increased commitment to PU.1+ cells within 24 hr, a time period
during which the vast majority of transplanted and similarly
defined HSC populations do not undergo more than one division
(Lo Celso et al., 2009). Together, our data thus indicate that MafB
deficiency enables M-CSF to instruct myeloid commitment
divisions in HSCs that generate increased PU.1+ MPPs.
Interestingly, PU.1+ MPPs can directly give rise to GMPs
without passing through a CMP stage (Arinobu et al., 2007),
which may explain the selectively myeloid-biased repopulation
advantage of MafB/ HSCs in the absence of effects on the
erythroid lineage. In contrast to the complete absence of any
effect on the T cell lineage and in addition to the strong myeloid
advantage, we also observed a slight and delayed advantage of
MafB/ HSCs in reconstituting the B cell compartment (Figure 1
and data not shown). This is consistent with the ability of PU.1 to
also instruct B cell fate at lower expression levels (DeKoter and
Singh, 2000).
HSC division can result in self-renewal or differentiation, but
the mechanisms controlling the different outcomes of a HSC divi-
sion remain unresolved. Several mutant mice with a HSC-cycling
phenotype have been characterized, but so far were exclusively
found to affect self-renewal (Orford and Scadden, 2008). Here,
we show that by contrast the higher proliferation rate of MafB/
HSCs appears to be dedicated to increased myeloid commit-
ment divisions. Consistent with this, MafB deficiency did not
result in abnormal expansion of the stem cell pool or myeloprolif-
erative disorders. Furthermore, it did not cause stem cell deple-
tion or compromise differentiation to other lineages, suggesting
that augmented myeloid commitment divisions occur in addition
rather than at the expense of other HSC divisions.
Evidence from both invertebrate and mammalian models
indicates that stem cells can undergo both asymmetric divisions
that give rise to mixed stem and differentiated daughter cell pairs
(S/D) and symmetric divisions with two stem cell daughter pairs
(S/S) or two differentiated cell daughter pairs (D/D) (Knoblich,
2008; Morrison and Kimble, 2006). Moreover, hematopoietic
stem and precursor cells in culture can change the relative
proportion of asymmetric divisions in response to external
cues such as cytokines or stromal cells (Takano et al., 2004; Wu
et al., 2007). Although we cannot exclude that on a population
basis in vivo, S/S division-buffered myeloid D/D type divisions
also contribute to increased myeloid commitment, our single-
cell experiments show that reduced MafB levels specifically
increased M-CSF-stimulated asymmetric divisions, giving rise
to PU.1/PU.1+ daughter pairs. This observation provides
a conclusive explanation as to why increased myeloid commit-
ment of MafB/ HSCs does not come at the expense of self-
renewal or other lineages, since asymmetric stem cell divisions
do not change the total number of stem cells and thus maintain
a stable stem cell pool that remains available for subsequent
self-renewal and generation of other lineages. MafB deficiency
therefore appears to enable enhanced myeloid commitment
without affecting self-renewal or other lineages by selectively
increasing asymmetric myeloid commitment divisions of HSCs.
Although the role of both lineage specific transcription factors
and cytokines in HSC commitment has been discussed (Enver
et al., 1998; Hu et al., 1997; Metcalf, 2008; Orkin and Zon,
2008; Sieweke and Graf, 1998; Zhang and Lodish, 2008), it is
not clear how the two regulatory systems may be integrated. It
has been proposed that HSC fate decisions may depend on
sensitivity thresholds of cytokine signaling (Zandstra et al.,
2000), but whether cytokines could play an instructive role in
lineage commitment has remained highly controversial (Enver
et al., 1998; Metcalf, 1998). Our results now indicate that
lineage-specific transcription factors such as MafB may play
a key role in HSCs by setting cytokine sensitivity thresholds
and that transcription factor expression below a certain level
could render external cues instructive. Such critical variations
in expression levels that we induced experimentally may occur
naturally through external cues, cell-intrinsic stochastic fluctua-
tion (Chang et al., 2008), or stably inherited epigenetic modifica-
tions (Dykstra et al., 2007; Jordan and Lemischka, 1990; Muller-
Sieburg et al., 2002). Indeed, by transplantation of individual
HSCs, Dykstra et al. have functionally defined a population of
so-called a cells with an intrinsically set myeloid lineage bias
that can be stably transmitted through serial transplantation.
To a certain extent, this resembles the properties of MafB/
HSCs, and it will be interesting to determine whether HSCs
can fix a certain differentiation preference by epigenetic repres-
sion of cell intrinsic threshold setters such as MafB.
Furthermore, the availability of M-CSF may also play an impor-
tant role in controlling HSC commitment divisions. Interestingly,
in the bone-marrow M-CSF is mainly produced by a subset of
osteoblasts and endothelial cells (Ryan et al., 2001) and thus
potentially in direct vicinity to endosteal and perivascular stem
cell niches (Adams and Scadden, 2006; Kiel and Morrison,
2008; Wilson and Trumpp, 2006). Both cell-intrinsic suscepti-
bility and levels of external cues may thus cooperate to control
HSC-specific commitment divisions. We predict that other
lineage-specific transcription factors besides MafB may similarly
act as threshold setters for other cytokines and thus control
the exit of HSCs toward different differentiation pathways. The
fine-tuned balance of these factors would thus result in an
appropriate response to the available external cues and thus
assure both adaptive and stable HSC behavior under different
physiological conditions.EXPERIMENTAL PROCEDURES
Mice, CFU-S Assays, and FACS Analysis
MafB/ (Blanchi et al., 2003) and PU.1-GFP reporter mice (Arinobu et al.,
2007) have been described. Age- and sex-matched Ly5.1 or F1 recipients
were reconstituted as described (Aziz et al., 2006) with competitor cells
from Ly5.1 fetal liver or F1 ACK lysed bone marrow (BM). Macroscopic anal-
ysis and serial transplantations of CFU-S was done as described (Siminovitch
et al., 1964) by IV injection of lethally irradiated C57BL/6J mice with 4 3 106
BM cells from primary transplants or secondary spleenocyte suspensions.
For FACS analysis, we used described staining protocols (Aziz et al.,
2006), published stem and progenitor cell definitions (Bryder et al., 2006),
FACSCanto, LSRII, and FACSAria equipment and DIVA software (Becton
Dickinson).
Cell Culture and Retroviral Infections
EGER-fms pro-T cells were cultured as described (Bourette et al., 2007) under
T cell (50 ng/ml rSCF, 10 ng/ml rIL-7, 1 mM b-estradiol [Sigma]) or myeloid
conditions (50 ng/ml rM-CSF). KSL cells were sorted into S clone SF-03
medium (Sanko Jyunyaku) with 10% FBS (SCM) and seeded at 60 cells/
96-well (uncoated U shape, Greiner) in 100 ml SCM, 20 ng/ml rSCF, 50 ng/ml
rTPO ± 100 ng/ml rM-CSF, rG-CSF, rGM-CSF, rIl-3, or human rFGF-a
(Biosource) or at 60 cells/96-well in SCM, 5 ng/ml rFlt3-L, 5 ng/ml rIL-7 on
irradiated OP9-DL1 stromal cells under the described conditions (Schmitt
and Zuniga-Pflucker, 2002). All cytokines were murine and from PeproTech
if not otherwise indicated.
MSCV-based retroviral vectors were constructed by PCR cloning comple-
mentary DNAs (cDNAs) of murine MafB or an activated M-CSFR mutant
(c-fms S301,S374, D30; Carlberg and Rohrschneider [1994]) under LTR control
and by replacement of the IRES-driven GFP with td-tomato cDNA (Clontech),
to generate MafB-GFP and M-CSFR*-tdTomato. shRNA sequences (Table S1)
were determined with RNAi Codex software (http://codex.cshl.edu/scripts/
newmain.pl) and cloned into LMP-GFP virus (Open Biosystems). Viral super-
natants were produced with fNXe cells (http://www.stanford.edu/group/
nolan) and used to infect EGER-fms or primary BM cells by a double 2h-spino-
culation with 8 mg/ml polybrene. To enrich for cycling KSL cells, BM was
harvested 24 hr after IP injection of 600 ml PBS containing 10 mg/ml cyclophos-
phamide (Sigma). For shFms and shPU.1/3 virus infection, fetal liver cells were
cultured 24 hr prior to infection in medium supporting stem cell amplification
(IMDM 15% FBS, 100 ng/ml rIl-11, 100 ng/ml rSCF, 50 ng/ml rFlt3L, 10 ng/ml
rTPO, 105 M b-Mercaptoethanol).
Western Blotting, Quantitative Real-Time PCR, and RT-PCR
Western blots were performed as described (Bakri et al., 2005) with anti-PU.1
antibody (Cell signaling, #2258) at 1:1000 dilution. Genomic DNA was
extracted with the DNeasy Mini kit (QIAGEN). Total RNA was isolated and
reverse transcribed with mMACS One-step T7 Template Kit (Miltenyi Biotec)
or extracted with the RNeasy Mini kit (QIAGEN), digested with DNase I
(QIAGEN), and reverse transcribed with SuperScript II (Invitrogen). For quan-
titative real-time PCR, we used Power SYBR Green PCR Master Mix and
a 7500 Fast Real Time PCR System sequence detection system (both
Applied Biosystem), following the manufacturers’ instructions. For primers,
see Table S1.
Fluorescence Microscopy
For single daughter pair analysis, PU.1 KSLF cells were directly sorted into
conical 384-well glass bottom plates (SensoPlate, Greiner) with 20 ml SCM,
20 ng/ml rSCF, 50 ng/ml rTPO, 100 ng/ml rM-CSF (myeloid SCM). Single cells
were revisited until the first division for a maximum of 40 hr, and daughter cells
were monitored for GFP expression with a Zeiss Axiovert 200 inverted micro-
scope.
For anti-PU.1 IF, 23 103 KSLF cells were seeded in V-shaped 96-well plates
(Greiner) in 100 ml myeloid SCM. Cells were fixed before or after culture in
myeloid SCM with PBS/2% paraformaldehyde (PFA) for 10 min at room
temperature, neutralized in PBS/100 mM glycine, washed 23 in PBS, incu-
bated for 30 min in PBS/2% BSA/2% FCS/2% donkey serum/0.1% saponin
(P buffer), 30 min with anti-PU.1 antibody (T-21, sc-352, Santa Cruz) in P bufferCell 138, 300–313, July 24, 2009 ª2009 Elsevier Inc. 309
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Figure 6. MafB Restricts M-CSF-Instructed Asymmetric Myeloid Commitment Divisions
(A) Relative MafB message levels in HSC-enriched PU.1 Flt-3 cells (PU.1- KSLF, gate A) and PU.1+ Flt-3+ progenitors (PU.1+ MPP, gate B) in the KSL fraction of
PU.1-GFP reporter mice (HPRT normalized qRT-PCR values).
(B) Representative profiles of PU.1-GFP expression in PU.1 KSLF cells (gate A in panel A) from MafB+/ and WT PU.1-GFP reporter mice before and after 20 hr
incubation with 100 ng/ml M-CSF or Il-3.
(C) PU.1 KSLF cells (gate A in panel A) of MafB+/ and WT PU.1-GFP reporter mice were directly sorted into 384-well plates with 100 ng/ml M-CSF containing
medium. Single cells were revisited until the first division and daughter cells monitored for GFP expression. Two representative samples each of PU.1/, PU.1+/
and PU.1+/+ daughter pairs, counts from two independent experiments, and proportions of division types are shown. **p = 0.01 by Pearson’s Chi square test.310 Cell 138, 300–313, July 24, 2009 ª2009 Elsevier Inc.
(1:200), washed 23 in P buffer, and incubated for 30 min with Alexa488-
donkey-anti-rabbit antibody (Molecular probes) in P buffer (1:1000). Finally,
cells were washed 23 in PBS, resuspended in 6 ml PBS, and dried to a glass
slide for 2 min at 37C. From randomly chosen cells in the DAPI channel, green
fluorescent images were acquired under identical settings with a Zeiss Axio-
plan2 and SmartCapture2 software.
B
C D
A Figure 7. Increased Myeloid Commitment
of MafB/ HSCs In Vivo
(A) Experimental strategy: CSFE-labeled HSCs
(CD150+ KSLF) were directly injected into the
spleen, which was recovered after 24 hr for immu-
nofluorescence staining.
(B) Representative examples of anti-PU.1 staining
(red) on sections containing a CSFE+ cell (green),
showing CFSE+ PU.1 (left) and CFSE+ PU.1+
(right) cells. Nuclear topro3, gray. Scale bars
represent 10 mm.
(C) Representative selection of individual PU.1+
and PU.1 cells from spleens injected with WT or
MafB/ HSCs showing anti-PU.1 staining (red),
CFSE label (green), and nuclear topro3 (blue).
(D) Quantification of two independent experiments
showing the percentage of PU.1+ cells of WT
(Exp1, n = 12; Exp2, n = 47) and MafB/ (Exp1,
n = 23; Exp2, n = 49) CFSE+ cells from 40 sections
per spleen.
For analysis of HSCs in vivo, 3500 to 7000
FACS-sorted CD150+ KSLF were stained for 10
min at 37C with 4 mM CFSE (Invitrogen) in PBS/
0.5% BSA, washed 33 in PBS/0.5% BSA, and in-
jected in 30 ml PBS into the spleen of anesthetized
mice. After 24 hr, spleens were embedded in OCT
(Tissue-Tek, Sakura) and frozen at 80C. Cryo-
stat sections (10 mm) were dried and fixed for 10
min in 4% PFA/PBS at room temperature. After
washes in PBS, slides were blocked for 1 hr at
room temperature in PBS/2% BSA/1% donkey
serum/1% FCS/0.1% saponin, incubated for 36
hr at 4C with anti-PU.1 polyclonal antibody (Santa
Cruz) in PBS/0.05% saponin (1:50), washed, and
incubated with secondary Alexa 546-donkey-
anti-rabbit antibody (Molecular Probes) in PBS/
0.05% saponin (1:500) and Torpo-3 (1:1000, Invi-
trogen). Slides were analyzed by confocal micros-
copy on a Zeiss LSM510 Meta. All IF samples were
mounted with ProLong Gold antifade (Molecular
Probes).
Proliferation Assays and Cell-Cycle
Analysis
Cell cultures were incubated for 1 hr with 10 mM
BrdU in appropriate medium. For in vivo analysis,
BM cells were harvested 16 hr after IV injection of
5 mg rM-CSF and incubated for 1 hr at 37C in
SCM/10 mM BrdU. Using a BrdU flow kit (Becton Dickinson) and following
the manufacturer’s instructions, after surface marker staining and fixation,
we labeled cells for 20 min at room temperature with anti-BrdU antibody,
incubated with 7-AAD for 10 min at room temperature, and analyzed by
FACS. For cell-cycle analysis of KSL subpopulations, BM cells were incu-
bated for 30 min at 37C in SCM containing 5 mM Hoechst 34580 (Invitrogen)(D) Extracts from HEK293 cells transfected with PU.1 and different anti-PU.1 shRNA expression constructs or empty control vector (EV) were probed by western
blotting for PU.1 or b-tubulin. Molecular weight is in kDa.
(E) Analysis of spleen 11 days after transplantation of Ly5.1 recipients with shPU.1/3-GFP retrovirus-infected MafB/ (KO) Ly5.2 fetal liver cells and WT F1
competitor cells. Representative FACS profiles of KO donor and WT competitor contribution to Mac-1+ myeloid cells in GFP (blue) or shPU.1/3-GFP-infected
GFP+ populations (green) and quantification of KO:WT ratios in GFP and GFP+ populations of Mac-1+ and Mac-1 spleen cells (n = 3).
Error bars indicate the standard error of the mean.Cell 138, 300–313, July 24, 2009 ª2009 Elsevier Inc. 311
before staining for cell surface markers and analysis of DNA content by
FACS.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, eight
figures, and one table and can be found with this article online at http://
www.cell.com/supplemental/S0092-8674(09)00518-2.
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